Abstract. Intrinsically Disordered Proteins (IDPs) are a class of proteins that have no sure tertiary or secondary structure in the natural state. They are widely found in nature and involved in cell signal transduction, regulation, and protein interactions with a wide range of human diseases related. The research of IDPs provides new opportunities for drug design, and many cancer-related diseases are associated with IDPs lacking of ordered structures. However, the structural dynamic properties of IDPs present a significant obstacle to directly targets for drug design due to lacking of ordered structures in IDPs. This paper reviews the current research on the drug design progress of IDPs, lists examples on the drug design of IDPs, and some potential drug targets that can be used in IDPs. Finally, it analyzes the obstacles and difficulties in the drug design of IDPs.
combined to form a helical structure; and after combine with asparagine hydroxylase that form a highly-stretched structure.
It is a good research direction that the design of small molecules hinders the formation of these unfavorable protein aggregates. Scientists can design small molecules to directly target the proper structure of such aggregated IDPs to prevent the occurrence of false folds, and to design non-toxic monomers or multimers for small molecules to stabilize such proteins, or design small molecules to directly accelerate the aggregation of such proteins, thereby minimizing the residence time of their toxic oligomers in the organism [8] . Now there are structural design based on these monomer's and oligomer's examples [9] .
Examples of Intrinsically Disordered Protein's Drug Design
From the statistical data, 79% of the cancer-related proteins, 66% of the signal transduction proteins, 66% of the cardiovascular disease-related proteins contained more than 30 Residues of continuous disordered fragments, but this kind of protein in total protein's set that accounted for only 13% [10] [11] . And p53 associated with apoptosis and cancer, BRCA-1/2 proteins associated with breast cancer, c-Myc/Max [12] [13] associated with various cancers, alpha-synuclein associated with neurodegenerative diseases, Tau and Aβ associated with Alzheimer's disease, and a series of prion proteins are either IDPs or have a greater degree of disorder.
AF9 is a Mixed Lineage Leukemia (MLL) fusion protein that causes carcinogenic transformation of hematopoietic cells. AF9 interacts with the most common fusion protein AF4 in acute leukemia. Bioinformatics analysis shows that fusion proteins usually exhibit a high degree of disordered structure. In the current example, both AF9 and AF4 are IDPs. Based on mapping studies, AF4-derived peptides have been developed to specifically interact with AF9 and demonstrate that AF4-AF9 interactions can be disrupted in vitro and in vivo [14] . Recently, AF9's nonpeptide inhibitors have also been successfully developed through high-throughput screening tests.
Intrinsically Disordered Proteins as a Potential Drug Target
Adapter molecule Crk (PDB ID 2EYY / 2EYZ) is also known as proto-oncogene c-Crk or p38. Which has several SH2 and SH3 structural domains and act as adapters for tyrosine kinases and small G proteins. It regulates survival, movement, proliferation and apoptosis during the process of transcription and cytoskeleton recombination of cells [15] . Crk overexpression has been identified as a cause of several human cancers, including breast cancer, ovarian cancer, lung cancer, brain cancer and gastric cancer. Therefore, the inhibition of Crk is an effective treatment for the treatment of these malignant tumors. For example, microRNAs have been used to attenuate Crk's translation process.
Proliferating cell nuclear antigen (PCNA) is an essential protein in DNA replication. A new type of protein p15PAF was identified as a PCNA-related factor by using PCNA as a bait in a yeast two-hybrid screening. p15PAF is located mainly in the nucleus, and p15PAF share sequences which bind to PCNA, with several other PCNA binding protein (including CDK inhibitor p21). And it will bind to p21-PCNA when p15PAF is overexpressed. Mutation of the sequence in p15PAF eliminates the binding activity of its PCNA. It is noteworthy that p15PAF was significantly increased expression in several types of tumors, especially in esophageal tumors. Like PCNA, p15PAF may have a wide range of implications in human cancers [16] .
CRKI (SH2-SH3) and CRKII (SH2-SH3-SH3) are used to regulate transcription and cytoskeleton recombination for cell growth and movement by tyrosine kinase attachment to a small G protein.
However, CRKII has a very low biological activity, phosphorylated CRKII is essentially non-bioactive, but CRKI exhibits significant biological activity. In conclusion, the molecular mechanisms are still elusive while underlying the different biological activities of CRK proteins. We determined the solution structure of CRKI, CRKII and phosphorylated CRKII by NMR, and identified the molecular mechanism that induced its activity. CRK plays an important role in regulating cell growth and motility in vivo, especially when it is a tyrosine kinase, which plays a role in transcriptional recombination during growth, movement, proliferation, differentiation and apoptosis. Thus, CRK is able to be an important effective therapeutic target possibly [17] .
Obstacles in the Drug Design of Intrinsically Disordered Proteins
At present, the main obstacle is the lack of a complete set of strategic mechanisms in the drug's design of IDPs. The traditional rational drug designs are dependent on the background of the three-dimensional protein structure for ordered protein, and it is not feasible to apply the traditional design drug method directly to natural disorder proteins. The structural dynamic properties of IDPs present a significant obstacle to drug design that directly targets its disorder. However, IDPs are usually present in highly dynamic conformation, and it is difficult to determine the exact structure by experimental or theoretical means. For most of IDPs, it is impossible to use traditional methods for drug design. At present, there is still a lot of questions to be answered clearly about the paradigm relation of sequence-structure-function yet, and a lot of research work is needed. Thus, most of the drug design cases for IDPs were conducted through high-throughput experimental screening, not by rational design. Therefore, new strategies need to be developed to better rationalize drug design for IDPs.
Summary
In this research, we briefly discussed the discovery of intrinsically disordered proteins as well as the content in the biological body. The possibility was researched while as a drug design of IDPs. Moreover, we summarize examples of successful drug design examples, effective drug targets, and drug design with potentially targeted IDPs. And these research analyzes the difficulties and possibilities of the solution, when the IDPs is used in drug design, which is currently encountered by. Finally, it is only possible to develop a new strategy to deal with the high dynamic characteristics of IDPs in order to make a breakthrough in the virtual screening of IDPs drug design.
